G.M. Mead

726 total citations
12 papers, 186 citations indexed

About

G.M. Mead is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, G.M. Mead has authored 12 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Surgery and 3 papers in Pathology and Forensic Medicine. Recurrent topics in G.M. Mead's work include Testicular diseases and treatments (5 papers), Lymphoma Diagnosis and Treatment (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). G.M. Mead is often cited by papers focused on Testicular diseases and treatments (5 papers), Lymphoma Diagnosis and Treatment (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). G.M. Mead collaborates with scholars based in United Kingdom. G.M. Mead's co-authors include Sarah Lowndes, Andrew Lister, M. Sokal, S.D. Fosså, Penny A. Cook, William G. Jones, J.T. Roberts, John Whitehead, Matthew R. Sydes and Stuart Kaye and has published in prestigious journals such as The Lancet, Annals of Oncology and European Urology.

In The Last Decade

G.M. Mead

12 papers receiving 180 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G.M. Mead United Kingdom 7 67 51 45 44 35 12 186
Cristina Iosif Romania 9 81 1.2× 99 1.9× 52 1.2× 81 1.8× 11 0.3× 34 275
G. Rangoni Italy 10 68 1.0× 111 2.2× 20 0.4× 69 1.6× 21 0.6× 26 362
Georges Garnier France 8 60 0.9× 96 1.9× 36 0.8× 47 1.1× 2 0.1× 16 214
M. Benchalal France 8 69 1.0× 94 1.8× 24 0.5× 49 1.1× 6 0.2× 20 178
Aurélie Vogt United States 6 72 1.1× 94 1.8× 20 0.4× 22 0.5× 3 0.1× 12 244
L K Rajeev India 9 59 0.9× 117 2.3× 71 1.6× 43 1.0× 3 0.1× 63 224
E. Lévy France 8 71 1.1× 124 2.4× 32 0.7× 55 1.3× 5 0.1× 32 279
V. Martínez-Taboada Spain 7 57 0.9× 13 0.3× 33 0.7× 14 0.3× 17 0.5× 11 280
Antonio García‐Escudero Spain 9 78 1.2× 36 0.7× 41 0.9× 57 1.3× 2 0.1× 21 223
S. Le Burel France 4 58 0.9× 263 5.2× 47 1.0× 18 0.4× 16 0.5× 7 344

Countries citing papers authored by G.M. Mead

Since Specialization
Citations

This map shows the geographic impact of G.M. Mead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G.M. Mead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G.M. Mead more than expected).

Fields of papers citing papers by G.M. Mead

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G.M. Mead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G.M. Mead. The network helps show where G.M. Mead may publish in the future.

Co-authorship network of co-authors of G.M. Mead

This figure shows the co-authorship network connecting the top 25 collaborators of G.M. Mead. A scholar is included among the top collaborators of G.M. Mead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G.M. Mead. G.M. Mead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Huddart, Robert, Anwar R. Padhani, G.M. Mead, et al.. (2007). 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: Preliminary report of MRC trial TE22 - The NCRI testis tumour clinical study group. UCL Discovery (University College London). 5 indexed citations
2.
Lowndes, Sarah, et al.. (2002). Stevens–Johnson syndrome after treatment with rituximab. Annals of Oncology. 13(12). 1948–1950. 79 indexed citations
3.
4.
Mead, G.M.. (2002). Management of oral mucositis associated with cancer chemotherapy. The Lancet. 359(9309). 815–816. 40 indexed citations
5.
Jones, William G., et al.. (2001). A randomised trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE18). European Journal of Cancer. 37. S157–S157. 13 indexed citations
6.
Wit, Ronald de, Paul Wilkinson, PHM de Mulder, et al.. (1999). Is 3BEP equivalent to 3BEP+1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study. UCL Discovery (University College London). 3 indexed citations
7.
Griffiths, Gareth, Gregory S. Sibley, G.M. Mead, et al.. (1999). Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. UCL Discovery (University College London). 16 indexed citations
8.
Fosså, S.D., Stuart Kaye, S. J. Harland, et al.. (1998). Adjuvant bleomycin, vincristine and cisplatin (BOP) for high risk clinical stage I (HRCS 1) non-seminomatous germ cell tumours (NSGCT) - a Medical Research Council (MRC) pilot study.. UCL Discovery (University College London). 12 indexed citations
9.
Mead, G.M., NM Bleehen, A. Gregor, et al.. (1998). Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in primary CNS lymphoma (PCL)- BR06.. UCL Discovery (University College London). 1 indexed citations
10.
Mead, G.M.. (1996). Raltitrexed, a new drug for advanced colorectal cancer. The Lancet. 347(9015). 1568–1569. 4 indexed citations
11.
Mead, G.M., et al.. (1993). Prognostic Factors in MetastaticIMon-Seminomatous Germ CellTumours: The Medical ResearchCouncil Studies. European Urology. 23(1). 196–201. 6 indexed citations
12.
Mead, G.M. & J. M. A. Whitehouse. (1989). Clinical aspects of Hodgkin's disease:Authors' reply. BMJ. 298(6671). 460.5–460. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Iosif Breakdown of academic impact, for papers by G. Rangoni Breakdown of academic impact, for papers by Georges Garnier Breakdown of academic impact, for papers by M. Benchalal Breakdown of academic impact, for papers by Aurélie Vogt Breakdown of academic impact, for papers by L K Rajeev Breakdown of academic impact, for papers by E. Lévy Breakdown of academic impact, for papers by V. Martínez-Taboada Breakdown of academic impact, for papers by Antonio García‐Escudero Breakdown of academic impact, for papers by S. Le Burel
Rankless by CCL
2026